NTT DOCOMO Ventures, Inc. (headquartered in Minato-ku, Tokyo, Japan; President & CEO: Minoru Etoh) announced today its investment, through the investment fund it operates, in MiRTeL Co., LTD. (headquartered in Hiroshima-shi, Hiroshima, Japan; Chairman & CEO: Hidetoshi Tahara, hereinafter referred to as "MiRTeL") that provides a genetic test named the "MiRTeL Test" by using its proprietary technology.
1 Overview of the investment
NTT DOCOMO Ventures, Inc., through the investment fund it operates, has subscribed for unsecured convertible bonds of MiRTeL.
MiRTeL is engaged in disease prevention by using its proprietary technology "MiRTeL Test," which screens people at a genetic level for potential diseases. NTT DOCOMO, INC. (headquartered in Chiyoda-ku, Tokyo, Japan; President & CEO: Kaoru Kato, hereinafter referred to as "DOCOMO") and MiRTeL will start a joint health innovation study to promote the nation's healthy longevity. By combining DOCOMO's ICT knowledge and MiRTeL's expertise on disease screening and prevention, we expect to create a new healthy longevity business.